Monoclonal-Antibody Therapy in Systemic Vasculitis
MONOCLONAL antibodies are potentially useful therapeutic agents in a variety of immunologically mediated diseases, offering the theoretical advantage of selective attack on cells implicated in the immunopathogenesis of these disorders. Antibodies to surface markers on lymphocytes, particularly T cel...
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 1990-07, Vol.323 (4), p.250-254 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | MONOCLONAL antibodies are potentially useful therapeutic agents in a variety of immunologically mediated diseases, offering the theoretical advantage of selective attack on cells implicated in the immunopathogenesis of these disorders. Antibodies to surface markers on lymphocytes, particularly T cells, have already demonstrated efficacy both in animal models and in clinical allograft rejection.
1
2
3
For this purpose, monoclonal antibodies can be used either to block vital receptors for antigen, adhesion, or growth factors or to block target cells by harnessing the various natural effector systems (complement and accessory cells) that are activated by the Fc regions of cell-bound antibodies. The optimal use . . . |
---|---|
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJM199007263230407 |